3.47  -0.13 (-3.61%)		06-12 16:00
Open: 3.6 High: 3.73 Volume: 1,563,039		Pre. Close: 3.6 Low: 3.44 Market Cap: 297(M)

Short term
Mid term
Targets	6-month :	4.39	1-year :	4.92
Resists	First :	3.76	Second :	4.21
Pivot price	3.39
Supports	First :	3.03	Second :	2.52
MAs	MA(5) :	3.42	MA(20) :	3.41
	MA(100) :	4.11	MA(250) :	3.87
MACD	MACD :	-0.2	Signal :	-0.3
%K %D	K(14,3) :	71.3	D(3) :	65
RSI	RSI(14): 45.7
52-week	High :	6.42	Low :	2.22

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ LRMR ] has closed below upper band by 37.7%. Bollinger Bands are 58.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	3.74 - 3.76	3.76 - 3.77
Low:	3.39 - 3.42	3.42 - 3.43
Close:	3.44 - 3.47	3.47 - 3.5

Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.

Wed, 27 May 2026
JP Morgan Initiates Coverage of Larimar Therapeutics (LRMR) with Overweight Recommendation - MSN

Wed, 20 May 2026
Larimar Therapeutics (LRMR) director receives 55,150 stock options grant - Stock Titan

Wed, 20 May 2026
Larimar Therapeutics (LRMR) awards 55,150 stock options to director - Stock Titan

Wed, 20 May 2026
[Form 4] Larimar Therapeutics, Inc. Insider Trading Activity - Stock Titan

Thu, 30 Apr 2026
Larimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich’s Ataxia - GlobeNewswire

Fri, 27 Mar 2026
Wedbush Raises its Price Target on Larimar Therapeutics (LRMR) to $13 - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	104 (M)
Shares Float	60 (M)
Held by Insiders	1.1 (%)
Held by Institutions	85.5 (%)
Shares Short	8,050 (K)
Shares Short P.Month	8,310 (K)

EPS	-2.12
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	1.5
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-57 %
Return on Equity (ttm)	-109.9 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-1.66
Qtrly Earnings Growth	0 %
Operating Cash Flow	-131 (M)
Levered Free Cash Flow	-71 (M)

PE Ratio	-1.64
PEG Ratio	0
Price to Book value	2.29
Price to Sales	0
Price to Cash Flow	-2.75

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.